Effective Letermovir Prophylaxis of CMV infection post allogeneic hematopoietic cell transplantation: Results from the French temporary authorization of use compassionate program.

D, Beauvais; C, Robin; A, Thiebaut; S, Alain; V, Coiteux; S, Ducastelle-Lepretre; A, Marçais; P, Ceballos; A, Xhaard; R, Redjoul; S, Nguyen; E, Brissot; M, Joris; P, Turlure; MT, Rubio; P, Chevallier; N, Bénard; C, Liautard; I, Yakoub-Agha

doi:10.1016/j.jcv.2022.105106

Public

Effective Letermovir Prophylaxis of CMV infection post allogeneic hematopoietic cell transplantation: Results from the French temporary authorization of use compassionate program.

Shared by NobleBlocks on Feb 15, 2022 • 12:00 AM UTC

Authors:

Beauvais D

Robin C

Thiebaut A

Abstract

We report the results of the French Temporary Authorization of Use (ATU) compassionate program of letermovir for primary prophylaxis conducted in 21 transplant centers. Patients were CMV seropositive allogeneic hematopoietic cell transplantation recipients and at high risk for CMV infection. Primary...

Subject

Cytomegalovirus

Cmv Infection

Primary Prophylaxis

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!